Shenzhen Kangtai Biological Products Management

Management criteria checks 3/4

Shenzhen Kangtai Biological Products' CEO is Xiang Miao, appointed in Dec 2021, has a tenure of 2.33 years. directly owns 0.17% of the company’s shares, worth CN¥38.39M. The average tenure of the management team and the board of directors is 2.3 years and 13.6 years respectively.

Key information

Xiang Miao

Chief executive officer

CN¥3.3m

Total compensation

CEO salary percentage	n/a
CEO tenure	2.3yrs
CEO ownership	0.2%
Management average tenure	2.3yrs
Board average tenure	13.6yrs

Recent management updates

Recent updates

CEO

Xiang Miao (50 yo)

2.3yrs

Tenure

CN¥3,337,100

Compensation

Mr. Xiang Miao has been President at Shenzhen Kangtai Biological Products Co., Ltd. since December 29, 2021 and serves as its Director and served as its Vice President and Secretary.

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Xiang Miao	President & Non-Independent Director	2.3yrs	CN¥3.34m	0.17% CN¥ 38.4m
Haifa Zheng	Vice Chairman & VP	15.6yrs	CN¥2.06m	2.22% CN¥ 505.2m
Hui Zhou	Chief Financial Officer	2.3yrs	CN¥1.01m	0.012% CN¥ 2.8m
Jiankai Liu	VP & Non-Independent Director	2.3yrs	CN¥3.40m	0.16% CN¥ 36.4m
Jin Tao	Board Secretary	2.3yrs	CN¥955.50k	0.014% CN¥ 3.1m

2.3yrs

Average Tenure

51yo

Average Age

Experienced Management: 300601's management team is considered experienced (2.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Xiang Miao	President & Non-Independent Director	no data	CN¥3.34m	0.17% CN¥ 38.4m
Haifa Zheng	Vice Chairman & VP	15.6yrs	CN¥2.06m	2.22% CN¥ 505.2m
Jiankai Liu	VP & Non-Independent Director	15.6yrs	CN¥3.40m	0.16% CN¥ 36.4m
Weimin Du	Chairman of the Board	15.6yrs	CN¥3.39m	25.74% CN¥ 5.9b
Zhiyun Lu	Chairman of the Supervisory Board	11.6yrs	no data	0.038% CN¥ 8.6m
Hak Ping Wu	Independent Director	2.3yrs	CN¥112.50k	no data
Feidong Wen	Vice Chairman	2.3yrs	CN¥1.82m	0.0081% CN¥ 1.9m

13.6yrs

Average Tenure

59yo

Average Age

Experienced Board: 300601's board of directors are seasoned and experienced ( 13.6 years average tenure).

Shenzhen Kangtai Biological Products Management

Management criteria checks 3/4

Key information

Recent management updates

Shenzhen Kangtai Biological Products Co., Ltd., Annual General Meeting, May 31, 2024

Shenzhen Kangtai Biological Products Co., Ltd., Annual General Meeting, May 31, 2024

Less than half of directors are independent

Insufficient new directors

Insufficient new directors

Recent updates

Shenzhen Kangtai Biological Products Co., Ltd., Annual General Meeting, May 31, 2024

Shenzhen Kangtai Biological Products Co., Ltd., Annual General Meeting, May 31, 2024

First quarter 2024 earnings released: EPS: CN¥0.05 (vs CN¥0.18 in 1Q 2023)

Shenzhen Kangtai Biological Products Co., Ltd. to Report Q1, 2024 Results on Apr 23, 2024

Investor sentiment improves as stock rises 17%

Investor sentiment improves as stock rises 17%

Shenzhen Kangtai Biological Products Co., Ltd. to Report Fiscal Year 2023 Results on Apr 23, 2024

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: EPS: CN¥0.17 (vs CN¥0.074 in 3Q 2022)

Shenzhen Kangtai Biological Products Co., Ltd. Announces Interim Profit Distribution Plan to Be Implemented (A Shares) for 2023, Payable on 13 October 2023

Shenzhen Kangtai Biological Products Co., Ltd. Approves 2023 Interim Cash Dividend

Shenzhen Kangtai Biological Products Co., Ltd. Proposes Interim Cash Dividend for the First Half of 2023

Second quarter 2023 earnings released: EPS: CN¥0.28 (vs CN¥0.14 loss in 2Q 2022)

First quarter 2023 earnings released: EPS: CN¥0.18 (vs CN¥0.25 in 1Q 2022)

Third quarter 2022 earnings released: EPS: CN¥0.29 (vs CN¥0.64 in 3Q 2021)

Investor sentiment improved over the past week

Less than half of directors are independent

Second quarter 2022 earnings released: CN¥0.53 loss per share (vs CN¥0.28 profit in 2Q 2021)

Shenzhen Kangtai Biological Products Co., Ltd. (SZSE:300601) announces an Equity Buyback for CNY 200 million worth of its shares.

Shenzhen Kangtai Biological Products Co., Ltd. Announces Final Cash Dividend for the Year 2021, Payable on 2 June 2022

Shenzhen Kangtai Biological Products Co., Ltd. Approves Final Cash Dividend for the Year 2021

Investor sentiment deteriorated over the past week

First quarter 2022 earnings released: EPS: CN¥0.40 (vs CN¥0.037 in 1Q 2021)

Insufficient new directors

Now 22% undervalued after recent price drop

Full year 2021 earnings released: EPS: CN¥1.88 (vs CN¥1.03 in FY 2020)

Investor sentiment improved over the past week

Now 22% undervalued after recent price drop

Third quarter 2021 earnings released: EPS CN¥1.02 (vs CN¥0.26 in 3Q 2020)

Insufficient new directors

Second quarter 2021 earnings released: EPS CN¥0.46 (vs CN¥0.39 in 2Q 2020)

Shenzhen Kangtai Biological Products Co., Ltd. Announces Philippine Food and Drug Administration Approval to BIOKANGTAI COVID-19 Vaccine for Phase III Clinical Trial in the Philippines

Phase III Clinical Fieldwork of the Inactivated COVID-19 Vaccine (Vero Cells) Independently Developed and Manufactured by Shenzhen Kangtai Biological Products Co., Ltd. is Officially Initiated in Malaysia

Shenzhen Kangtai Biological Products Co., Ltd. Not to Pay Dividend for the Year 2020

First quarter 2021 earnings released: EPS CN¥0.037 (vs CN¥0.004 in 1Q 2020)

New 90-day low: CN¥135

New 90-day high: CN¥181

New 90-day low: CN¥149

Third quarter earnings released

New 90-day low: CN¥157

New 90-day high - CN¥227

Shenzhen Kangtai Biological Products Co., Ltd. to Report First Half, 2020 Results on Jul 21, 2020

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age